BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210309
DTEND;VALUE=DATE:20210312
DTSTAMP:20260515T154321
CREATED:20201022T103840Z
LAST-MODIFIED:20201022T104916Z
UID:27595-1615248000-1615507199@www.pharmajournalist.com
SUMMARY:Gene Therapy for Blood Disorders 2021
DESCRIPTION:2020 has been an exciting year for Gene Therapies targeting Blood Disorders. Despite FDA’s recent rejection of BioMarin’s hemophilia gene therapy program\, the clinical landscape is progressing quickly with Pfizer and Sangamo kicking off their phase 3 and bluebird bio receiving European approval for their beta-thalassemia candidate. With pipelines advancing and emerging companies joining the blood disorders field\, it is essential for gene therapy developers to communicate and share lessons learned to accelerate their programs to market. \n \nThe 2nd Gene Therapy for Blood Disorders meeting is taking place in March 2021\, focusing on the clinical and commercial challenges of developing gene therapies targeting hemophilia\, sickle cell disease and beta thalassemia. Evaluate the best strategies for a commercial launch in blood disease and optimize your trial design to ultimately transform your clinical candidates into a commercial reality. \nTo know more about Gene Therapy for Blood Disorders please click here.
URL:https://www.pharmajournalist.com/event/gene-therapy-for-blood-disorders-2021/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210311
DTEND;VALUE=DATE:20210313
DTSTAMP:20260515T154321
CREATED:20210226T095658Z
LAST-MODIFIED:20210226T100244Z
UID:29127-1615420800-1615593599@www.pharmajournalist.com
SUMMARY:2nd Annual MarketsandMarkets Infectious Disease Diagnostics and Point-Of-Care Testing Virtual Conference
DESCRIPTION:The Diagnostics sector has emerged as a prominent game changer in healthcare\, because of many technological advancements taking place within the field. As diagnostics is a key for making the treatment decisions\, it needs to be quicker\, précised\, and accurate. \nPoint-of-care testing (POCT) is a growing testing. Today\, you may see POCT in a hospital with handheld gadgets or small testers in emergency department\, extensive care setting\, popular clinical wards\, and imaging facilities. And market analyses that the world is moving from critical laboratory testing to testing for quick and accurate results at the patient’s point of care. \n \nIn the era of improved diagnostics\, our 2nd Annual Virtual Event on Infectious Disease Diagnostics and Point-Of-Care Testing will serve as a networking place for Diagnostics professional\, Industrial specialists\, and solution providers to address the rising innovation in its discipline and the way it can be used as disease prevention tool. \nEvent Website: https://bit.ly/3gNnkOq \nRegistration link: https://bit.ly/3oRX7kH
URL:https://www.pharmajournalist.com/event/2nd-annual-marketsandmarkets-infectious-disease-diagnostics-and-point-of-care-testing-virtual-conference/
LOCATION:Virtual
ORGANIZER;CN="Marketsandmarkets":MAILTO:aradhna.robert@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210311
DTEND;VALUE=DATE:20210312
DTSTAMP:20260515T154321
CREATED:20210226T105316Z
LAST-MODIFIED:20210226T111537Z
UID:29175-1615420800-1615507199@www.pharmajournalist.com
SUMMARY:MarketsandMarkets BioPharma Manufacturing CRYSTAL BALL EVENT (Time Zone - 9AM EST)
DESCRIPTION:High growth markets which contribute to 20% of your revenues today will contribute 80% in the next 5 years. Identify these new revenue sources at MarketsandMarkets’s Crystal Ball event \nThe end product sales in bioproduction market are expected to grow at over `15% to be a $305 Bn market in 2025. Numerous engines are expected to fuel its growth – Cell Therapy\, Gene Therapy\, Monoclonal Antibodies\, Vaccines\, biosimilars and biobetters\, plasma therapy as well as others. \nA host of attractive\, high growth opportunities such as single use systems\, Lab Scale and CGMP manufacturing and R&D\, Crispr and other Gene editing tools and technologies\, Novel downstream bioprocessing methods etc could be pursued. Participants such as CROs\, CMOs\, Bioprocess solutions manufacturers\, Biobanks\, automation technology providers etc can benefit from this unprecedented growth over the next 5 years. \nThis Crystal Ball event focuses on learning more about the most promising opportunities in the Bioproduction ecosystem\, as seen through the lens of eminent CXOs in this space \nEvent Website: https://bit.ly/3qJYdQF  \nRegistration link: https://bit.ly/2Mcpg8i 
URL:https://www.pharmajournalist.com/event/marketsandmarkets-biopharma-manufacturing-crystal-ball-event-time-zone-9am-est/
LOCATION:Virtual Event
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210315
DTEND;VALUE=DATE:20210318
DTSTAMP:20260515T154321
CREATED:20201214T152316Z
LAST-MODIFIED:20201214T152538Z
UID:28302-1615766400-1616025599@www.pharmajournalist.com
SUMMARY:Targeting RNA Congress 2021
DESCRIPTION:Targeting RNA is set to be the next big thing; 85% of human genome transcribed to RNA but only 3% translated into proteins\, therefore making it an obvious target. With Risdiplam being approved by the FDA in August\, and several major collaborations also being penned throughout 2020\, including a $190 million deal between Arrakis and Roche\, it seems like a good time to target these protein precursors. \n \nThe Targeting RNA Congress will return for 2021\, March 15-17\, and will take a look at the latest techniques to analyse and predict protein structure\, as well as hearing from leading researchers and industry on how to incorporate learnings from RNA biology into potent and selective ligands to help prevent\, rather than treat\, disease. \nKey Outcomes from the summit include: \n\nLearn where to target your RNA molecules after exploring the newest biophysical techniques to analyse RNA structure\, including NMR\, Cryo-EM\, and in silico modelling with Silvi Rouskin\, (MIT)\, Wah Chiu (Stanford University) and Hashim Al Hashimi (Duke University).\nUnderstand what makes a druggable RNA target and hear from expert RNA biologists to advise how best to drug your favourite RNA targets with Anima Biotech and Craig Blain (Arrakis).\nGet translational insights into what considerations are important when creating a small molecule that targets RNA by learning how to develop tools for assessment of RNA targets with Amanda Garner (University of Michigan)\nHear what new techniques can help to drug these tricky targets\, including RNAi\, RNA degraders and RIBOTACs with Gene Yeo (UCSD)\, Jonathan Hall (Zurich) and Matt Disney (Scripps and Expansion).\n\nTo know more about Targeting RNA Congress please click here.
URL:https://www.pharmajournalist.com/event/targeting-rna-congress-2021/
LOCATION:Virtual Summit EST Timezone
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210315
DTEND;VALUE=DATE:20210317
DTSTAMP:20260515T154321
CREATED:20201223T083652Z
LAST-MODIFIED:20201223T083652Z
UID:28371-1615766400-1615939199@www.pharmajournalist.com
SUMMARY:SMi’s 2nd Annual AI in Drug Discovery
DESCRIPTION:Chaired by: Darren Green\, Director of Molecular Design & Senior Fellow\, GSK \nSponsored by: OpenEye Scientific Software \nExploring the latest Innovations in Machine Learning for Enhancing Discovery Pipelines \nSMi is proud to present its 2nd Annual AI in Drug Discovery Conference\, taking place on the 15-16 March 2021. \nWith the global Artificial Intelligence (AI) in Drug Discovery Market size expected to exceed $3\,900 million by 2027\, the conference agenda will encompass key drivers leading the way into a shorter\, cheaper\, and more successful R&D era. The conference will be a particular focus on case studies from leading pharma and biotech\, as well as a close-up view on the paradigm shift from undruggable targets to ‘challenging to drug’. \n \nFurthermore the event will focus on 4 key themes: machine learning and automation for improved drug discovery pipelines; effective prediction of compound properties; data robustness and curation; innovative use of AI for rare and undruggable diseases\, and will highlight key case studies across these themes\, uncovering key developments in pharma of data optimization and to aid therapeutic discovery. Real-world examples of AI in structure-based drug design and patient relevant data will be explored in eye-opening detail \nEvent Hashtag: #SMiAIDrugDis \nHIGHLIGHTS FOR 2021 INCLUDE: \n\nDiscover the latest innovations in AI-based drug discovery platforms\nEngage in case study presentations from leading pharma and biotech companies on machine learning and improved drug discovery pipelines\nUnderstand how AI can be effectively implemented to enhance productivity\nDelve into best practices in data quality\, curation\, and validation\nExplore how AI is being used to unlock therapies that have evaded traditional drug discovery\n\nKEY SPEAKERS INCLUDE \n\nNoor Shaker\, CEO\, Glamorous AI\nMaria Luisa Pineda\, Co-Founder & CEO\, Envisagenics\nEd Addison\, Co-founder\, Chairman\, and CEO\, Cloud Pharmaceuticals\nLiling Warren\, Director\, Head of Translational Medicine Statistics\, Teva Pharmaceuticals\nLili Peng\, Associate Director Scientific Ecosystem Analytics Lead\, Biogen\nMark De Pristo\, CEO\, BigHat Biosciences\nPhilipe Moingeon\, Head of Immuno-inflammation\, Servier\nHugo Ceulemans\, Scientific Director\, Discovery Data Sciences\, Janssen\nPeter Henstock\, Machine Learning & AI Lead\, Pfizer\nNaheed Kurji\, CEO\, Cyclica\n\nWHO SHOULD ATTEND \nCEOs\, Presidents\, Vice Presidents and Global Heads\, Executive Directors\, Vice President & Global head\, Principal Scientists\, Heads of Business Development\, Directors of Pharma/Biotech firms.
URL:https://www.pharmajournalist.com/event/smis-2nd-annual-ai-in-drug-discovery/
LOCATION:Online Access Only
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210322
DTEND;VALUE=DATE:20210324
DTSTAMP:20260515T154321
CREATED:20201028T124553Z
LAST-MODIFIED:20201028T124553Z
UID:27686-1616371200-1616543999@www.pharmajournalist.com
SUMMARY:Parallel Trade 2021 – Virtual conference: online access only
DESCRIPTION:Exploring the challenges\, practices and drivers in the aftermath of the transition for Parallel Trade \nSMi present’s its 15th annual Parallel Trade virtual conference\, taking place virtually on the 22nd and the 23rd March 2021. As the only parallel trade conference in Europe\, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade. \n\nThe 2021 event will be more significant than ever before due to the transition period after Brexit coming to an end this year. As such\, the UK will no longer be part of the EU free market. This will mean increased medicines prices\, reduced access to some specialist drugs and greater risk of supply chain shortages. In a post-Brexit environment\, exhaustion of rights will cease to apply to the UK\, making import and export a costly business and in a worst-case scenario could effectively kill parallel distribution. \nThis conference will bring together industry experts to discuss the challenges and drivers of the industry\, including the EU regulatory landscape and the impact of the FMD (Falsified Medicines Directive). The conference will also provide global insights on Parallel trade and will reflect on key takeaways for other member states. \nRegister online for only £999: www.parallel-trade.com/pjwl    \nThe benefits of attending: \nLearn new perspectives and case studies through presentation\, panel discussions and interactive workshops from industry KOLs. Engage in a platform discussion inclusive of all different facets of parallel trade in analysing the overall state of the market. Explore the effects and impact of the Falsified Medicines Directive and how to best comply to these practices. Collaborate and share ideas of how a hard Brexit will impact the EU market and affect parallel trade practices. Discover what the industry has learnt from COVID-19 and the impact on export bans. \nPlus\, one post-conference interactive workshop \nWorkshop: The law of parallel trade: past\, present and future\nWorkshop Leaders:\nChristopher Stothers\, Partner\, Bruckhaus Freshfields Deringer\nSharon Malhi\, Senior Associate\, Antitrust\, Competition and Trade\, Bruckhaus Freshfields Deringer \n Who should attend: \nVice President/ Heads of/General Managers: \n\nInternational Trade and Relations\nSupply Chain Development – Brexit\nBrexit Implementation\nMarket Access\nSupply Chain Manager\nParallel trade reporting\nRegulatory Affairs\nIP\nPurchasing\nPolicy Patent Operations\nEuropean Affairs\nSupply and Demand\nAttorney\nDistribution\n\nAdditional Contact Info:\nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk\nLinkedIn: @SMi Pharma\nTwitter: @SMiPharm #SMi #SMiParallel
URL:https://www.pharmajournalist.com/event/parallel-trade-2021-virtual-conference-online-access-only/
LOCATION:Virtual Event
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210323
DTEND;VALUE=DATE:20210326
DTSTAMP:20260515T154321
CREATED:20210119T095042Z
LAST-MODIFIED:20210119T095042Z
UID:28574-1616457600-1616716799@www.pharmajournalist.com
SUMMARY:FcRn-Targeted Therapies for Autoimmune Disorders Summit
DESCRIPTION:The neonatal Fc receptor (FcRn) plays a fundamental role in the transcytosis\, half-life extension\, and recycling of human serum albumin and IgG\, however in the case of more than 100+ rare and autoimmune disorders\, this can not only be detrimental\, but lethal to the health of the individual. Following the high profile J&J-Momenta deal\, UCB’s rozanolixizumab expects a Ph3 readout in H1 2021 and Argenx’s efgartigimod awaits US filing by the end of 2020\, other large players are poised to bring their candidates through the clinic in rapid succession. \n \nThe digital FcRn-Targeted Therapies for Autoimmune Disorders Summit is not only the first\, but the only dedicated meeting that brings you the most up to date clinical and commercial developments utilizing FcRn antagonists in rare and autoimmune diseases. \nThe 3-day program will bring together a wealth of knowledge into the complexities of the FcRn-IgG interaction and the therapeutic strategies which are being employed to yield clinical efficacy. Expect to hear from industry leaders showcasing clinical candidates aimed at disrupting the autoantibody interaction and increasing the clearance of pathogenic IgG from the body. \nJoin 100+ experts online from companies such as CSL Behring\, Eli Lilly\, Roche\, Momenta\, Alexion\, Argenx and more to discuss FcRn MOA\, preclinical model selection and translation\, high throughput assays for ligand screening\, IgG engineering\, and DMPK modelling to ensure best in class medicines are brought to patients. Including an exclusive workshop lead by the FDA who will be exploring protein immunogenicity to better understand FcRn drug development.
URL:https://www.pharmajournalist.com/event/fcrn-targeted-therapies-for-autoimmune-disorders-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210323
DTEND;VALUE=DATE:20210325
DTSTAMP:20260515T154321
CREATED:20210226T101236Z
LAST-MODIFIED:20210226T101236Z
UID:29150-1616457600-1616630399@www.pharmajournalist.com
SUMMARY:5th Annual MarketsandMarkets High Potent Medicines Virtual Conference (CET TIME ZONE)
DESCRIPTION:One of the major challenges faced by the players in this market\, especially CMOs that offer HPAPI manufacturing services\, is the continual evolution of industry standards\, technologies\, and regulations. \nOwing to their target release characteristics\, HPAPIs find major applications in target therapies for cancer. Globally\, there is a significant growth in the incidence of cancer. Diseases like musculoskeletal diseases\, glaucoma\, and specifically cancer have a significant impact on the health status of people worldwide\, with comparatively higher growth rates in developing countries. \nThe 5th Annual MarketsandMarkets High Potent Medicines Virtual Conference to be held on 23-24 March 2021. This conference would address the challenges in continual evolution of industry standards\, technologies\, and regulations. Leading experts from the industry will discuss the strategies for both in-house manufacturing and outsourcing by presenting expert keynote presentations\, live case studies and breakthrough panel discussions. \nEvent Website https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-high-potent-medicines-virtual-conference/ \nRegistration link: https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-high-potent-medicines-virtual-conference/register  
URL:https://www.pharmajournalist.com/event/5th-annual-marketsandmarkets-high-potent-medicines-virtual-conference-cet-time-zone/
LOCATION:Virtual
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210324
DTEND;VALUE=DATE:20210326
DTSTAMP:20260515T154321
CREATED:20201119T113716Z
LAST-MODIFIED:20201119T113716Z
UID:27982-1616544000-1616716799@www.pharmajournalist.com
SUMMARY:Cytokine-Based Cancer Immunotherapies Summit
DESCRIPTION:Pioneering Research to Develop Safe & Effective Immunomodulators to Stimulate the Soluble Tumor Microenvironment \nThe renewed interest in the anti-tumor properties of cytokines has led to an increase in the number of clinical trials that explore the safety and efficacy of cytokine-based drugs\, not only as single agents\, but also in combination with other immunomodulatory drugs. \n \nTherapeutically targeting of soluble immune modulators in the tumor microenvironment (TME) has been shown to create a ‘hot’ tumor\, increasing T cell infiltration and improving response rates to immune checkpoint blockade treatment. The immuno-oncology research community is pivoting towards engineering soluble factors and cytokines to transform the TME into an immunostimulatory state\, acting as a complementary strategy to a suite of cancer immunotherapies approaches. \nThe virtual Cytokine-Based Cancer Immunotherapies Summit has been established to give drug developers insight into the latest clinical advancements and stimulate discussions around how to take immuno-oncology combinations forward to meet the vast unmet need of cancer patients. \nJoin us and leading experts from Roche\, CytomX\, Philogen\, Bristol-Myers Squibb\, Novartis and many more to discuss how to reduce toxicity and achieve an efficacious dose\, determining the mechanisms of action and hear the latest data coming out of the clinic. \nTo know more about Cytokine-Based Cancer Immunotherapies Summit please click here.
URL:https://www.pharmajournalist.com/event/cytokine-based-cancer-immunotherapies-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210324
DTEND;VALUE=DATE:20210326
DTSTAMP:20260515T154321
CREATED:20210114T091620Z
LAST-MODIFIED:20210122T141247Z
UID:28478-1616544000-1616716799@www.pharmajournalist.com
SUMMARY:Animal Microbiome Congress
DESCRIPTION:The 4th Annual Animal Microbiome Congress taking place on the 24-25th March 2021 will provide the latest clinical data and facilitate interactions between academia and industry to accelerate the commercialization of animal microbiome research. This global market is forecast to grow to 9.7 billion by 2028 due to demand for innovation from the rapidly growing meat\, aquaculture\, and pet healthcare industries to meet an increasing need to replace antibiotics and satisfy the world’s growing hunger for protein. Over 4 years and 7 events\, we have built an international animal microbiome community of 600+ people from 30+ countries. \n \nThrough comprehensive industry-academic discussion panels\, engaging keynotes\, interactive roundtables\, and virtual networking this congress will enable participants to be at the forefront of modulating the animal microbiome to meet commercial goals\, sustainably and safely. Our goal is to support smart interactions between business and academia to enable participants to capitalize on the growing global animal microbiome market. Due to this year’s virtual format\, we have advanced our networking capabilities to help you recreate the unexpected interactions that drive the future of your work. We have incorporated: network roulette enabling 30 + chance encounters\, Deep Dive Roundtable groups of 9 people working together to tackle industry issues\, interactive content delivery to facilitate discussion and pre-arranged meetings to broaden your network strategically. \nJoin us and discover the critical breakthroughs on: uncovering the full functional potential of the microbiome in aquaculture\, production\, and companion animals\, improving health outcomes for production and companion animals\, reducing the cost of animal ownership and making farming more sustainable\, and translating academic research into commercial products whilst steering through challenging regulatory hurdles. \nBook now to join us in unlocking the full functional potential of the Animal Microbiome.
URL:https://www.pharmajournalist.com/event/animal-microbiome/
LOCATION:Virtual
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210324
DTEND;VALUE=DATE:20210327
DTSTAMP:20260515T154321
CREATED:20210226T115030Z
LAST-MODIFIED:20210226T115030Z
UID:29181-1616544000-1616803199@www.pharmajournalist.com
SUMMARY:8th Edition MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference ( Time Zone - CENTRAL EUROPEAN TIME (CET)
DESCRIPTION:The 8th Edition Biomarker and Companion Diagnostics Virtual Conference scheduled to be held on 25 – 26 March 2021 would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers\, Precision Medicine and Big Data. \nRegarding commercialization of biomarkers\, leading industry and academic experts would share their case studies focusing on advancements in companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers. \nEvent Website https://events.marketsandmarkets.com/8th-edition-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference/ \nRegistration link: https://events.marketsandmarkets.com/8th-edition-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference/register
URL:https://www.pharmajournalist.com/event/8th-edition-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference-time-zone-central-european-time-cet/
LOCATION:Virtual
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210325
DTEND;VALUE=DATE:20210327
DTSTAMP:20260515T154321
CREATED:20210226T103615Z
LAST-MODIFIED:20210226T103615Z
UID:29166-1616630400-1616803199@www.pharmajournalist.com
SUMMARY:5th Annual MarketsandMarkets Infection Control\, Sterilization & Decontamination Virtual Conference (GMT)
DESCRIPTION:Based on the survey on 1\,000 hospitals in 33 countries\, European Centre for Disease Prevention and Control (ECDC) estimates that that on any given day\, one in 18 patients in a European hospital has healthcare-associated infection (HAIs). Most the countries (26 out of 33) reported the major three types of HAIs: pneumonia and lower respiratory tract infection\, surgical site infection and urinary tract infection. \nThe estimated number of patients in UK acquiring HAIs is approx. 300\,000 a year\, according to a report by National Institute for Health and Care Excellence (NICE). It costs the NHS approximately £1 billion a year\, and £56 million of this is estimated to be incurred after patients are discharged from hospital. NHS has now adopted no-tolerance policy towards spread of HAIs. \nMarketsandMarkets is organizing 5th Annual Infection Control\, Sterilization and Decontamination in Healthcare Virtual Conference\, scheduled for 25th & 26th March 2021\, aiming at providing platform to experts from hospitals\, academia\, and government institutions discussing the innovations\, challenges\, and future aspects of infection control\, decontamination\, and sterilization. \nEvent Website: https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-infection-control-sterilization-decontamination-virtual-conference/ \nRegistration link: https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-infection-control-sterilization-decontamination-virtual-conference/register
URL:https://www.pharmajournalist.com/event/5th-annual-marketsandmarkets-infection-control-sterilization-decontamination-virtual-conference-gmt/
LOCATION:Virtual
ORGANIZER;CN="Marketsandmarkets":MAILTO:aradhna.robert@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210329
DTEND;VALUE=DATE:20210401
DTSTAMP:20260515T154321
CREATED:20210208T084530Z
LAST-MODIFIED:20210208T084530Z
UID:28854-1616976000-1617235199@www.pharmajournalist.com
SUMMARY:LEAP HR: Life Sciences Spring Edition
DESCRIPTION:LEAP HR: Life Sciences Spring Edition is your best opportunity to uncover the radical strategies biopharma people leaders are putting in place to ensure they are a flexible employer of choice in a competitive industry. \nThis unique forum is shining a light on how the boldest life sciences HR leaders are rethinking the HR function and redefining the workforce of the future in order to continue to innovate and thrive in the face of change. \nStep inside the HR innovation that is making a difference to employees\, patients and customers – and leave with a brand new playbook for the people function to thrive in a post-vaccine world. \nTo know more about LEAP HR: Life Sciences Spring Edition please click here.
URL:https://www.pharmajournalist.com/event/leap-hr-life-sciences-spring-edition/
LOCATION:Exclusive Virtual Conference
ORGANIZER;CN="Hanson Wade":MAILTO:info@leap-hr.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210330
DTEND;VALUE=DATE:20210402
DTSTAMP:20260515T154321
CREATED:20201202T152441Z
LAST-MODIFIED:20201202T152747Z
UID:28146-1617062400-1617321599@www.pharmajournalist.com
SUMMARY:Gene Therapy Comparability
DESCRIPTION:The inaugural Gene Therapy Comparability Summit is the only industry dedicated meeting to ensuring your manufacturing processes are effective and comparable at every stage of development\, supporting a seamless transition to the larger scales required for commercialization. \nThis meeting will unite large pharma and innovative biotechs including Pfizer\, Biogen\, BioMarin and Takeda as they share best practices\, lessons learned and analytical data across the comparability lifecycle. \n \nFocused specifically on enhancing your gene therapy comparability approach\, join us to ensure you maintain safety\, quality\, consistency and efficacy throughout scale-up from clinical to commercial-scale manufacturing\, and satisfy regulatory demands to avoid costly delays to clinical programs. \nIncorporating insights from leading CMC\, Regulatory\, Analytical and Process Development experts\, this is your opportunity to gain extensive technical information on challenges like ensuring manufacturing processes are comparable when changing facilities and cell lines\, developing effective bioassays for use in comparability studies and handling the limited gene therapy lots available. \nJoin your peers online and discover: \n\nHow Biogen defined a robust comparability strategy for late phase gene therapy products\nGain insights into the planning and considerations for a comparability study and risk assessment and understand what defines process comparability vs analytical comparability with Amicus Therapeutics\nHear from the National Institute of Biology and discover if results of non-related analytical methods can be directly compared\nLearn from the Italian Medical Agency and take a deep dive into regulatory expectations for ATMP comparability and comparability exercises\nExplore next generation sequencing (NGS) and how its application can be utilized for comprehensive rAAV genome characterization with Biogen\nBetter understand the challenges associated with limited batch retention and sample availability in the context of comparability and learn best practices for mitigating such challenges with Gyroscope Therapeutics\n\nView the full event guide to find out more!
URL:https://www.pharmajournalist.com/event/gene-therapy-comparability/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR